Wang Wei, Du Yao, Zhang Xiaohe
Second Department of Orthopedics, Zhongxian People's Hospital, Chongqing, 404300, China.
Department of Orthopaedics, Qijiang District People's Hospital, Chongqing, 401420, China.
Inflammopharmacology. 2025 Jun 11. doi: 10.1007/s10787-025-01799-7.
The objective of this study was to comprehensively analyze the therapeutic effects of combined oral nimesulide and sodium hyaluronate on inflammatory factors (metalloproteinase [MMP]-3, MMP-9, interleukin [IL]-1, and tumor necrosis factor [TNF]-α) and pain intensity in traumatic knee osteoarthritis (TKO).
A total of 100 patients with TKO were enrolled into an experimental (Exp) group (oral nimesulide sustained-release capsule + injection of sodium hyaluronate into the knee cavity) and a control (Ctrl) group (oral nimesulide sustained-release capsules), with 50 cases in each group. The visual analog scale (VAS) score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, inflammatory factors, quality of life and clinical efficacy were compared between the two groups.
VAS and WOMAC scores of patients in the Exp group after treatment were greatly lower in contrast to those in the Ctrl group (P < 0.05). Meanwhile, the levels of MMP-3, MMP-9, interleukin (IL)-1, and tumor necrosis factor α (TNF-α) in the joint fluid of patients in the Exp group after treatment were markedly lower and exhibited obvious difference with those in the Ctrl group (P < 0.05). Additionally, the overall treatment effectiveness (OTE) in the Exp group was remarkably higher, which demonstrated a visible difference in comparison to the OTE in the Ctrl group (P < 0.05). The Exp group exhibited significantly higher scores in physical function, social function, and mental health after 1, 2, and 3 years of treatment compared to the Ctrl group. Additionally, the score for bodily pain was significantly lower in the Exp group than in the Ctrl group (P < 0.05).
The combination of nimesulide and intra-articular injection of sodium hyaluronate effectively reduced pain intensity and the severity of arthritis in patients, thereby enhancing clinical efficacy.
本研究旨在全面分析口服尼美舒利与透明质酸钠联合应用对创伤性膝骨关节炎（TKO）患者炎症因子（基质金属蛋白酶[MMP]-3、MMP-9、白细胞介素[IL]-1和肿瘤坏死因子[TNF]-α）及疼痛强度的治疗效果。
将100例TKO患者纳入实验组（口服尼美舒利缓释胶囊+膝关节腔内注射透明质酸钠）和对照组（口服尼美舒利缓释胶囊），每组50例。比较两组患者的视觉模拟评分（VAS）、西安大略和麦克马斯特大学骨关节炎指数（WOMAC）评分、炎症因子、生活质量及临床疗效。
治疗后实验组患者的VAS和WOMAC评分显著低于对照组（P<0.05）。同时，治疗后实验组患者关节液中MMP-3、MMP-9、白细胞介素（IL）-1和肿瘤坏死因子α（TNF-α）水平明显降低，与对照组相比差异显著（P<0.05）。此外，实验组的总体治疗有效率（OTE）显著更高，与对照组的OTE相比差异明显（P<0.05）。与对照组相比，治疗1、2和3年后，实验组患者在身体功能、社会功能和心理健康方面的评分显著更高。此外，实验组的身体疼痛评分显著低于对照组（P<0.05）。
尼美舒利与关节腔内注射透明质酸钠联合应用可有效降低患者的疼痛强度和关节炎严重程度，从而提高临床疗效。
